BrightGene Bio‑Medical Technology Co., Ltd. (SHA: 688166) announced that BGM0504, its independently developed dual GLP‑1 (glucagon‑like peptide‑1) and GIP (glucose‑dependent insulinotropic polypeptide) receptor agonist, has been approved for clinical trials in China for the treatment of adult type 2 diabetes (T2D).
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | China regulatory authority (NMPA/CDE pathway) |
| Action | Clinical trial approval |
| Product | BGM0504 – dual GLP‑1/GIP receptor agonist |
| Indication | Adult type 2 diabetes |
| Announcement Date | 13 Oct 2026 |
| Sponsor | BrightGene Bio‑Medical Technology (SHA: 688166), in‑house developed |
| Next Steps | Clinical trial initiation in T2D; phase and timelines Not disclosed |
Drug Profile & Mechanism of Action
- Molecule: BGM0504, an in‑house developed dual agonist of both the GLP‑1 and GIP receptors.
- Dual‑Pathway Activation: Effectively activates the downstream signaling pathways of both receptors, producing complementary incretin‑mediated biological effects.
- Glycemic Control: Demonstrated blood glucose–lowering activity, the core rationale for the new type 2 diabetes indication.
- Weight Reduction: Exhibits weight‑lowering effects, supporting parallel development in overweight/obesity.
- Beyond Metabolic Syndrome: Shows potential for treating metabolic dysfunction‑associated steatotic liver disease (MASLD), indicating strong therapeutic promise across multiple metabolic conditions.
Clinical Development Footprint
| Program | Region | Status |
|---|---|---|
| Phase I – Overweight/Obesity | China and United States | Completed |
| Phase II – Overweight/Obesity | China | Full participant enrollment completed |
| Type 2 Diabetes | China | Newly approved for clinical trials (Oct 2026) |
Market Impact & Outlook
- T2D Indication Expansion: The new diabetes clearance extends BGM0504’s clinical footprint beyond weight management into the vastly larger type 2 diabetes market, mirroring the multi‑indication strategy of approved dual incretin agonists.
- Dual GLP‑1/GIP Class Momentum: BGM0504 joins the fast‑growing dual GLP‑1/GIP receptor agonist class, whose combined mechanism delivers synergistic glycemic control and weight reduction versus single‑agonist therapies.
- China‑U.S. Development Foundation: With Phase I completed in both China and the U.S. and Phase II obesity enrollment complete in China, BrightGene has de‑risked early development before scaling into additional metabolic indications.
- MASLD Optionality: Early potential in metabolic dysfunction‑associated steatotic liver disease – a condition with limited approved therapies and high cardiometabolic comorbidity overlap – adds a differentiated long‑term value driver to the program.
- BrightGene Pipeline Strategy: The approval reinforces BrightGene (SHA: 688166)’s transition from its peptide/CDMO heritage into a clinical‑stage metabolic disease innovator with a wholly owned, multi‑indication asset.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding clinical trial progression, regulatory timelines and therapeutic potential of BGM0504. Actual results may differ materially due to risks including trial outcomes, safety and efficacy in diabetes and obesity populations, competitive dynamics in the incretin class, and evolving regulatory requirements in China and the United States.-Fineline Info & Tech
